Dr. Sahenk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
555 S 18th St
Columbus, OH 43205Phone+1 614-722-6200Fax+1 614-722-3273
Education & Training
Ohio State University HospitalResidency, Neurology, 1975 - 1978- Ohio State University HospitalResidency, Internal Medicine, 1974 - 1975
- Ohio State University HospitalResidency, Physical Medicine and Rehabilitation, 1972 - 1974
Hacettepe University FOMClass of 1972
Certifications & Licensure
OH State Medical License 1978 - 2026
IL State Medical License 1977 - 1984- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A Start of enrollment: 2025 Apr 01
- NT-3 Levels and Function in Individuals With CMT Start of enrollment: 2019 Nov 13
Publications & Presentations
PubMed
- Concurrent nodular lymphocytic myositis and myasthenia gravis. A case report.Eleonora S D'Ambrosio, Matti D Allen, Burcak Ozes, Zarife Sahenk
Neuromuscular Disorders. 2024-12-01 - AAV1.tMCK.NT-3 gene therapy improves phenotype inmouse model of Charcot-Marie-Tooth Type 4C.Burcak Ozes, Lingying Tong, Kyle Moss, Morgan Myers, Lilye Morrison
Brain Communications. 2024-01-01 - 16 citationsLong-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.Jerry R Mendell, Zarife Sahenk, Kelly J Lehman, Linda P Lowes, Natalie F Reash
Muscle & Nerve. 2024-01-01
Journal Articles
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, Richard Shell, JAMA Neurology
Authored Content
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJune 2020
Press Mentions
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2ASeptember 3rd, 2021- First Global CMT Research Convention Planned for SeptemberJune 16th, 2021
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to Its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular DystrophyMay 8th, 2019- Join now to see all
Grant Support
- NT-3 Gene Therapy To Improve Peripheral Nerve Function Induced By Genetic DefectNational Institute Of Neurological Disorders And Stroke2010–2011
- Histopathology CoreEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
- Histopathology CoreNational Institute Of Neurological Disorders And Stroke2007–2010
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
